CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230,845
- in 7 filings, $1.6M under 10b5-1 plans
Net −$2,230,845. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-06 | Bauer Jake Director | Grant or award · Stock Option (right to buy) | +20,491 | 20,491 | ||
| 2025-02-06 | Ballal Rahul D. Director | Grant or award · Stock Option (right to buy) | +20,491 | 20,491 | ||
| 2025-02-06 | Patel Anish CHIEF OPERATING OFFICER | Grant or award · Stock Option (right to buy) | +171,000 | 171,000 | ||
| 2025-02-06 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Grant or award · Stock Option (right to buy) | +171,000 | 171,000 | ||
| 2025-02-06 | Kintz Samuel PRESIDENT AND CEO | Grant or award · Stock Option (right to buy) | +490,000 | 490,000 | ||
| 2025-02-06 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (right to buy) | +171,000 | 171,000 | ||
| 2025-02-06 | Collins Helen Louise CHIEF MEDICAL OFFICER | Grant or award · Stock Option (right to buy) | +171,000 | 171,000 | ||
| 2025-02-05 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +1,000 | $2.48 | $2K | 14,000 |
| 2025-02-05 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −1,000 | $22.52 | $23K | 13,000 |
| 2025-02-05 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −1,000 | 146,056 | ||
| 2025-01-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +3,250 | $2.48 | $8K | 16,250 |
| 2025-01-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −3,250 | $21.59 | $70K | 13,000 |
| 2025-01-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −3,250 | 147,056 | ||
| 2025-01-07 | Patel Anish CHIEF OPERATING OFFICER | Option exercise 10b5-1 | +10,700 | $1.12 | $12K | 10,700 |
| 2025-01-07 | Patel Anish CHIEF OPERATING OFFICER | Option exercise 10b5-1 | +2,000 | $2.48 | $5K | 12,700 |
| 2025-01-07 | Patel Anish CHIEF OPERATING OFFICER | Option exercise 10b5-1 | +9,000 | $2.48 | $22K | 21,700 |
| 2025-01-07 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −20,260 | $24.15 | $489K | 1,440 |
| 2025-01-07 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −1,440 | $24.56 | $35K | 0 |
| 2025-01-07 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −6,577 | $24.17 | $159K | 336,734 |
| 2025-01-07 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −90 | $24.60 | $2K | 336,644 |
Page 13 of 37 · 724 trades